Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in patients with congestive heart failure (CHF) and/or hyponatremia (HYP)

被引：0
|
作者：
Van Wart, SA [1 ]
Cirincione, BB [1 ]
Ludwig, EA [1 ]
Chen, X [1 ]
Shoaf, S [1 ]
Grasela, TH [1 ]
Mallikaarjun, S [1 ]
机构：
[1] Cognigen Corp, Otsuka Maryland Res Inst, Buffalo, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2006年 / 79卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2005.12.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P1 / P1
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling of Tolvaptan and Diuretic Use on Fluid and Electrolyte Balance in Healthy Subjects
    Van Wart, Scott
    Shoaf, Susan
    Mallikaarjun, Suresh
    Mager, Donald
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S43 - S44
  • [42] Effect of tolvaptan on congestive heart failure patients with reduced stroke volume
    Kobayashi, M.
    Watanabe, M. W.
    Paku, Y. P.
    Iwasaki, Y. I.
    Imai, Y. I.
    Takata, Y. T.
    Yamashina, A. Y.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 88 - 89
  • [43] DEVELOPMENT OF A PHARMACOKINETIC (PK)/PHARMACODYNAMIC (PD) MODEL TO EVALUATE THE IMPACT OF PK VARIATION ON PD FOR EXTENDED RELEASE METOPROLOL FORMULATIONS
    Sharma, V. D.
    Trame, M. N.
    Schmidt, S.
    Fang, L. L.
    Lesko, L. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S9 - S9
  • [44] Pharmacokinetic (PK) and pharmacodynamic (PD) of immunosuppressive drugs in patients awaiting for a liver tranplantation
    Kamar, Nassim
    Canivet, Cindy
    Boehler, Torsten
    Lavit, Michel
    Galvani, Sylvain
    Salvayre, Robert
    Muscari, Fabrice
    Klupp, Jochen
    Thomsen, Mogens
    Rostaling, Lionel
    TRANSPLANT INTERNATIONAL, 2007, 20 : 142 - 142
  • [45] Tolvaptan reduces readmission rates in acute heart failure patients with hypervolemic hyponatremia
    Wagoner, L. Lynne
    Walton, C. E.
    Walton, E. K.
    Cassidy, R.
    Dietrich, D. L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 36 - 36
  • [46] ANALYSIS OF HEALTH CARE OUTCOME FOR CONGESTIVE HEART FAILURE (CHF) PATIENTS
    Ugiliweneza, B.
    VALUE IN HEALTH, 2010, 13 (03) : A176 - A176
  • [47] The prevalence and morbidity of anemia in hospitalized patients with congestive heart failure (CHF)
    Ayyoub, F
    Soi, V
    Rao, S
    Asfandiyar, S
    Shafi, S
    Frinak, S
    Besarab, A
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) : A19 - A19
  • [48] The efficacy of tolvaptan in congestive heart failure patients with and without hypoalbuminemia: a pilot study
    Okabe, T. Toshitaka
    Yakushiji, T.
    Ebara, S.
    Yamashita, K.
    Yamamoto, M. H.
    Hoshimoto, K.
    Amemiya, K.
    Isomura, N.
    Araki, H.
    Ochiai, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 336 - 337
  • [49] The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study
    Okabe, Toshitaka
    Yakushiji, Tadayuki
    Igawa, Wataru
    Ono, Morio
    Kido, Takehiko
    Ebara, Seitaro
    Yamashita, Kennosuke
    Yamamoto, Myong Hwa
    Saito, Shigeo
    Hoshimoto, Koichi
    Amemiya, Kisaki
    Isomura, Naoei
    Araki, Hiroshi
    Ochiai, Masahiko
    CARDIOVASCULAR THERAPEUTICS, 2015, 33 (05) : 275 - 281
  • [50] Comparison of Prognosis Either Continuous Tolvaptan Intake or not for Congestive Heart Failure Patients
    Takeuchi, Ryosuke
    Omote, Mayuko
    Kodama, Keita
    Hosoya, Natsuko
    Kageyama, Shigetaka
    Watanabe, Yuzo
    Sugiyama, Hirofumi
    Murata, Koichiro
    Nawada, Ryuzo
    Onodera, Tomoya
    JOURNAL OF CARDIAC FAILURE, 2016, 22 (09) : S214 - S214
12345